3 Macular Degeneration Clinical Trials in St. Petersburg, FL (2026)

Q: How do I join a clinical trial in St. Petersburg?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the St. Petersburg research site will contact you.

Recruiting Macular Degeneration Studies in St. Petersburg

NCT07441642Recruiting

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)....

St. Petersburg, FLPHASE2272 participantsNovartis Pharmaceuticals

View Study Details

NCT05986864Recruiting

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the ph...

St. Petersburg, FLPHASE168 participantsSkyline Therapeutics (US) Inc.

View Study Details

NCT05626114Recruiting

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related mac...

St. Petersburg, FLPHASE260 participantsGenentech, Inc.

View Study Details

About Macular Degeneration Clinical Trials in St. Petersburg

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.

There are currently 3 macular degeneration clinical trials recruiting participants in St. Petersburg, FL. These studies are seeking a combined 400 participants. Research is being sponsored by Novartis Pharmaceuticals, Skyline Therapeutics (US) Inc., Genentech, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Macular Degeneration Clinical Trials in St. Petersburg — FAQ

Are there macular degeneration clinical trials in St. Petersburg?

Yes, there are 3 macular degeneration clinical trials currently recruiting in St. Petersburg, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in St. Petersburg?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the St. Petersburg research site will contact you about next steps.

Are clinical trials in St. Petersburg free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many St. Petersburg studies also compensate for your time and travel.

What macular degeneration treatments are being tested?

The 3 active trials in St. Petersburg are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.

Data updated July 22, 2026 from ClinicalTrials.gov